COVID-19

[Nature Reviews Microbiology] The authors delineate the structural features of SARS-CoV-2 from the whole viral particle to the individual viral proteins and discuss their functions as well as their potential as targets for therapeutic interventions.

[CohBar, Inc.] CohBar, Inc. announced the United States Patent and Trademark Office has granted a patent, US No. 11,111,271, covering CohBar’s lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating NASH.

[AzurRx BioPharma, Inc.] AzurRx BioPharma, Inc. announced the activation of seven new clinical trial sites in India for the ongoing RESERVOIR trial evaluating FW-1022. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections.

[COVID-19 Immunity Task Force] More than 7 million Canadians suffer from immune-mediated inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related conditions. The COVID-19 Immunity Task Force and Vaccine Surveillance Reference Group will supporting a nationwide study that will assess COVID-19 vaccine effectiveness, safety and vaccine hesitancy in this potentially vulnerable group of people.

[City of Hope (BusinessWire, Inc.)] City of Hope is now enrolling patients in a Phase II clinical trial of its COH04S1 vaccine that is the first to study the safety and effectiveness of an investigational vaccine in blood cancer patients who have received a bone marrow transplant or CAR T therapy.

[Molecular Medicine] Researchers used a data-driven approach, combining results from the screening of a large transcriptomic database and molecular docking analyses, with in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19.